Dacomitinib & Non-small-cell lung cancer (NSCLC) (EGFR m)

In the context of Dacomitinib & Non-small-cell lung cancer (NSCLC) (EGFR m), Dacomitinib is approved by both the FDA and EMA for the treatment of Non-small-cell lung cancer (NSCLC) (EGFR m), specifically for classical activating EGFR mutations. The FDA approved dacomitinib on 27 September 2018 as first‑line treatment for patients with metastatic NSCLC harboring EGFR exon 19 deletion or exon 21 L858R substitution mutations (1, 2). The European Commission approved dacomitinib in April 2019 as monotherapy for first‑line treatment of adult patients with locally adv…